DUBLIN--(BUSINESS WIRE)--The "Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Central Nervous System dealmaking
Chapter 3 -Financial deal terms for Central Nervous System partnering
Chapter 4 - Leading Central Nervous System deals and dealmakers
Chapter 5 - Central Nervous System contract document directory
Chapter 6 - Central Nervous System dealmaking by therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/7b8jtm/global_central?w=4
